NYSE · Medical - Devices

BIO (BIO) Stock

$330.54 +4.47% NYSE: BIO Healthcare

Valuation

MetricValue
Price$330.54
Market Cap$8.94B
P/E Ratio10.29
P/B Ratio1.04
P/S Ratio3.00
EPS (TTM)$0.00
52-Week High$343.12
52-Week Low$228.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE10.20%
ROA7.19%
ROCE3.64%
Gross Margin10.45%
Operating Margin10.49%
Net Margin6.52%
Debt/Equity0.20
Current Ratio5.62

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.9B$2.8B$2.7B$2.6B$2.6B
Operating Profit$500.0M$483.0M$338.0M$269.0M$271.0M
Net Profit$4.3B$-3.6B$-637.0M$-1.8B$760.0M
EPS$140.83$-121.79$-21.82$-65.36$27.87
Op Margin17.1%17.2%12.7%10.5%10.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$17.8B$13.5B$12.3B$9.4B$10.6B
Total Liabilities$4.1B$3.9B$3.6B$2.8B$3.1B
Cash$471.0M$434.0M$404.0M$488.0M$532.0M
Borrowings$223.0M$1.4B$1.4B$1.4B$1.5B

Latest News

BIO: Raising target price to $313.00 Argus Research · Jul 15, 2026 Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis) GlobeNewswire · Jun 29, 2026 Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035 at a 8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) GlobeNewswire · Jun 24, 2026 Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? Motley Fool · Jun 22, 2026 Global Fluorescent In Situ Hybridization Probe Market Size/Share Worth USD 2.27 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis) GlobeNewswire · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$669.0M$194.0M$375.0M$455.0M$532.0M
Investing Cash Flow$-931.0M$-1.3B$-136.0M$-349.0M$-347.0M
Financing Cash Flow$-52.0M$-212.0M$-425.0M$-218.0M$-298.0M
Net Cash Flow$-196.0M$-37.0M$-30.0M$85.0M$40.0M
Free Cash Flow$536.0M$80.0M$218.0M$266.0M$375.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA18.38
FCF Yield4.59%
Quick Ratio3.21
Interest Coverage5.53
Return 1Y23.52%
Return 3Y-27.16%
Return 5Y-55.33%

Ownership

Insiders Held16.34%
Institutions Held94.45%
Institutions Float Held112.90%
Institutional HolderSharesReport Date
First Eagle Investment Management, LLC2,602,7722026-03-31
Blackrock Inc.1,680,0602026-03-31
Dimensional Fund Advisors LP1,089,3232026-03-31
Vanguard Capital Management LLC831,1652026-03-31
Vanguard Portfolio Management LLC829,1862026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGNAlign Technology, Inc. $169.29 +1.36% 27.86 $12.12B 0.00%
ATR $136.77 +2.10% 19.32 $8.73B 1.66%
CRL $232.51 -0.90% -54.59 $11.20B 0.00%
DVADaVita Inc. $236.58 +0.48% 23.20 $15.18B 0.00%
GMED $80.19 +2.48% 20.18 $10.81B 0.00%

About BIO

BIO is led by CEO Norman D. Schwartz, employs 7,450 people, headquartered in Hercules, US, publicly traded since 1980.

BIO stock trades at $330.54 with a market capitalization of $8.94B. The stock is valued at a price-to-earnings (P/E) ratio of 10.29, price-to-book of 1.04, price-to-sales of 3.00. Over the past 52 weeks the stock has ranged between $228.40 and $343.12, and currently trades 3.7% below its 52-week high.

On profitability, BIO generates a return on equity (ROE) of 10.20%, return on capital employed of 3.64%, an operating margin of 10.49%, a net profit margin of 6.52%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides